Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Notable Labs, Ltd. NTBLQ

Healthcare  —  Biotechnology
0.00 0.00 NaN as of 24 Sep
Market cap
$2.4M
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Notable Labs, Ltd. (NTBLQ) Business Profile

Updated before January 2025

Company Overview

Notable Labs, Ltd. (NTBLQ) is a biotechnology company that focuses on leveraging advanced technologies to develop personalized treatment options for cancer patients. Founded in 2014 by Matt De Silva, the company was established with the mission of improving the lives of cancer patients by identifying the most effective therapies tailored to their unique biological profiles. Headquartered in San Francisco, California, Notable Labs operates at the intersection of precision medicine and artificial intelligence, utilizing cutting-edge tools to revolutionize cancer treatment.

The company’s leadership team comprises experienced professionals from the fields of biotechnology, oncology, and data science. Matt De Silva, the founder, envisioned a patient-centric approach to cancer treatment after witnessing the challenges faced by his father during his battle with cancer. The leadership team also includes experts in clinical research, drug development, and computational biology, ensuring a multidisciplinary approach to achieving the company’s goals.

Core Business Segments

Personalized Drug Testing Platform

Notable Labs’ flagship offering is its personalized drug testing platform. This platform uses patient-derived cancer cells to test a wide range of FDA-approved drugs and investigational therapies. By analyzing how these drugs interact with the patient’s unique cancer cells, the platform identifies the most promising treatment options. This approach minimizes trial-and-error in cancer treatment and improves patient outcomes.

AI-Driven Data Analytics

The company integrates artificial intelligence and machine learning into its drug testing platform to analyze vast datasets and uncover patterns that may not be immediately apparent to human researchers. This AI-driven approach enhances the accuracy and efficiency of the drug selection process, making it a cornerstone of Notable Labs’ operations.

Clinical Trial Matching

Notable Labs also offers a clinical trial matching service that connects patients with ongoing clinical trials for therapies that align with their specific cancer profiles. This service not only benefits patients by providing access to cutting-edge treatments but also supports pharmaceutical companies in recruiting suitable candidates for their trials.

Business Model

Notable Labs operates on a B2B and B2C model. On the B2B side, the company collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance drug development and clinical trial processes. Revenue is generated through partnerships, licensing agreements, and service fees for its drug testing and data analytics platforms.

On the B2C side, Notable Labs offers its personalized drug testing services directly to patients and their oncologists. Patients pay for the testing service, which provides them with actionable insights into the most effective treatment options for their specific cancer type.

The company’s business model is built on the principles of innovation, collaboration, and patient-centricity. By integrating advanced technologies with a deep understanding of oncology, Notable Labs aims to transform the way cancer is treated.

Strategic Direction

Notable Labs is committed to expanding its services and enhancing its technological capabilities. The company’s strategic goals include:

  • Service Growth: Expanding the reach of its personalized drug testing platform to more patients and healthcare providers globally.
  • Sustainability Goals: Implementing eco-friendly practices in its operations and reducing the environmental impact of its laboratory processes.
  • New Product Categories: Exploring the development of new diagnostic tools and expanding its offerings to include other diseases beyond cancer.
  • Partnerships: Strengthening collaborations with pharmaceutical companies and research institutions to accelerate drug discovery and development.

Competitive Landscape

Notable Labs operates in a highly competitive biotechnology sector. Key competitors include:

  • Foundation Medicine: A leader in genomic profiling and precision medicine.
  • Caris Life Sciences: Specializes in molecular profiling and AI-driven cancer diagnostics.
  • Tempus: Focuses on data-driven precision medicine and AI-powered analytics.
  • Guardant Health: Known for its liquid biopsy tests and cancer diagnostics.

Despite the competition, Notable Labs differentiates itself through its unique combination of personalized drug testing, AI-driven analytics, and patient-centric services.

Risk Factors

Notable Labs faces several risks that could impact its operations and growth:

  • Market Dependence: The company’s revenue is heavily reliant on the adoption of its drug testing platform and services.
  • Regulatory Challenges: Navigating the complex regulatory landscape for medical devices and diagnostics can be time-consuming and costly.
  • Supply Chain Disruptions: Dependence on specialized equipment and reagents makes the company vulnerable to supply chain issues.
  • Competition: Intense competition in the biotechnology sector could limit market share and profitability.
  • Economic Factors: Economic downturns and changes in healthcare funding could affect the company’s revenue streams.

Recent Developments

In recent years, Notable Labs has made significant strides in advancing its technology and expanding its market presence. Key developments include:

  • AI Enhancements: Upgrading its AI algorithms to improve the accuracy and speed of drug testing results.
  • Global Expansion: Establishing partnerships with healthcare providers in Europe and Asia to offer its services to a broader patient base.
  • New Collaborations: Partnering with leading pharmaceutical companies to support drug development and clinical trials.
  • COVID-19 Impact: Adapting its operations to address challenges posed by the pandemic, including supply chain disruptions and changes in patient access to healthcare services.

Investment Considerations

Strengths

  • Innovative Technology: Cutting-edge drug testing platform and AI-driven analytics.
  • Patient-Centric Approach: Focus on improving patient outcomes through personalized treatment.
  • Strong Leadership: Experienced team with expertise in oncology, biotechnology, and data science.
  • Market Potential: Growing demand for precision medicine and personalized cancer treatments.

Risks

  • Regulatory Hurdles: Challenges in obtaining approvals for new products and services.
  • Competitive Pressure: Intense competition from established players in the biotechnology sector.
  • Economic Uncertainty: Potential impact of economic downturns on healthcare spending.

Conclusion

Notable Labs, Ltd. (NTBLQ) is at the forefront of precision medicine, leveraging advanced technologies to revolutionize cancer treatment. With its innovative drug testing platform, AI-driven analytics, and patient-centric approach, the company is well-positioned to address the growing demand for personalized cancer therapies. While challenges such as regulatory hurdles and competition exist, Notable Labs’ strong leadership and commitment to innovation provide a solid foundation for future growth. As the company continues to expand its services and explore new opportunities, it remains a promising player in the biotechnology sector.